Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group

被引：0
|
作者：
Schmiegel, W. H.
Reinacher-Schick, A.
Freier, W.
Dietrich, G.
Arnold, D.
Kanzler, S.
Geissler, M.
Graeven, U.
Hegewisch-Becker, S.
Schmoll, H.
机构：
[1] Ruhr Univ, Bochum, Germany
[2] Ctr Oncol, Hildesheim, Germany
[3] Bietigheim Hosp, Bietigheim, Germany
[4] Martin Luther Univ Halle Wittenberg, Halle, Germany
[5] Johannes Gutenberg Univ Mainz, Mainz, Germany
[6] Community Hosp, Esslingen, Germany
[7] Maria Hilf Hosp, Monchengladbach, Germany
[8] Ctr Oncol, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4034
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group
    Moosmann, Nicolas
    von Weikersthal, Ludwig Fischer
    Stauch, Martina
    Hass, Holger G.
    Dietzfelbinger, Herrmann
    Oruzio, Daniel
    Klein, Stefan
    Zellmann, Klaus
    Decker, Thomas
    Schulze, Mathias
    Abenhardt, Wolfgang
    Puchtler, Gerhard
    Kappauf, Herbert
    Mittermueller, Johann
    Haberl, Christopher
    Schalhorn, Andreas
    Jung, Andreas
    Stintzing, Sebastian
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1050 - 1058
  • [32] Capecitabine/irinotecan (Caplri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study.
    Grothey, A
    Jordan, K
    Kellner, O
    Constantin, C
    Dietrich, G
    Kroening, H
    Mantovani, L
    Schlichting, C
    Forstbauer, H
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 253S - 253S
  • [33] PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB (RHUMAB VEGF) AND OXALIPLATIN PLUS CAPECITABINE (XELOX) IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    Sarmiento, R.
    Frustaci, S.
    Torino, F.
    Ravaioli, A.
    Mattioli, R.
    Gebbia, V.
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 144 - 144
  • [34] Phase II study of the combination of bevacizumab (Rhumab VEGF) and oxaliplatin plus capecitabine (Xelox) in patients with advanced colorectal cancer
    Sarmiento, R.
    Frustaci, S.
    Bonadonna, A.
    Ravaioli, A.
    Oliviero, G.
    Mattioli, R.
    Tarnburrano, T.
    Gebbia, V
    Agueli, R.
    Torino, F.
    Lo Noce, V
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 86
  • [35] A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
    Willeke, F.
    Horisberger, K.
    Kraus-Tiefenbacher, U.
    Wenz, F.
    Leitner, A.
    Hochhaus, A.
    Grobholz, R.
    Willer, A.
    Kaehler, G.
    Post, S.
    Hofheinz, R-D
    BRITISH JOURNAL OF CANCER, 2007, 96 (06) : 912 - 917
  • [36] Neoadjuvant bevacizumab (BEV) combined with capecitabine (C) and standard radiation therpay (RT) in locally advanced rectal cancer (LARC): A phase II study
    Torino, F.
    Cascinu, S.
    Ciardiello, F.
    Ballestrero, A.
    Lencioni, M.
    Filippelli, G.
    Martignetti, A.
    Granetto, C.
    Sarmiento, R.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 57 - 57
  • [37] A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer
    F Willeke
    K Horisberger
    U Kraus-Tiefenbacher
    F Wenz
    A Leitner
    A Hochhaus
    R Grobholz
    A Willer
    G Kähler
    S Post
    R-D Hofheinz
    British Journal of Cancer, 2007, 96 : 912 - 917
  • [38] A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer
    Voest, E. E.
    Snoeren, N.
    Schouten, S. B.
    Bergman, A. M.
    van Werkhoven, E.
    Loosveld, O. J. L.
    van Gulik, T. M.
    Smit, J. M.
    Cats, A.
    Boven, E.
    Hesselink, E.
    Rijken, A.
    Tol, M.
    Dalesio, O.
    Verheul, H. M.
    Tollenaar, R. A.
    van der Sijp, J.
    Rinkes, I. Borel
    van Hillegersberg, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
    Andre, T.
    Saunders, M. P.
    Kanehisa, A.
    Gandossi, E.
    Fougeray, R.
    Causse-Amellal, N.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 250 - 250
  • [40] Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
    Koopman, M.
    Antonini, N. F.
    Douma, J.
    Wals, J.
    Honkoop, A. H.
    Erdkamp, F. L. G.
    de Jong, R. S.
    Rodenburg, C. J.
    Vreugdenhil, G.
    Akkermans-Vogelaar, J. M.
    Punt, C. J. A.
    ANNALS OF ONCOLOGY, 2006, 17 (10) : 1523 - 1528
12345